Literature DB >> 19039677

Two acute psychotic episodes after administration of bupropion: a case of involuntary rechallenge.

Hervé Javelot1, Alexandre Baratta, Luisa Weiner, Thierry Javelot, Cathy Nonnenmacher, Jean-Frédéric Westphal, Michaël Messaoudi.   

Abstract

Bupropion is an antidepressant drug also used as a smoking cessation aid, which inhibits norepinephrine and dopamine re-uptake. Given its pharmacological properties, it has been associated with reports on psychosis and acute delirious episodes. Case We report the case of a patient with schizoaffective disorder who developed two psychotic episodes respectively after a four and a two-day administration of sustained-release (SR) bupropion at a dose of 150 mg/day. To our knowledge, this is the first reported case of involuntary rechallenge with bupropion SR during a smoking cessation program. Conclusion There is a serious risk of incorrectly identifying bupropion as only a therapy for nicotine withdrawal without taking the precaution of exploring possible psychiatric co-morbidity with addiction. Our case illustrates the problem.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19039677     DOI: 10.1007/s11096-008-9272-x

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  15 in total

1.  Bupropion-induced psychosis.

Authors:  W T Howard; J K Warnock
Journal:  Am J Psychiatry       Date:  1999-12       Impact factor: 18.112

2.  A case of bupropion-associated delirium.

Authors:  S R Dager; A J Heritch
Journal:  J Clin Psychiatry       Date:  1990-07       Impact factor: 4.384

3.  Acute psychosis following sustained release bupropion overdose.

Authors:  Tzong-Shi Wang; I-Shin Shiah; Chin-Bin Yeh; Chuan-Chia Chang
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-11-23       Impact factor: 5.067

4.  Acute psychosis after bupropion treatment in a healthy 28-year-old woman.

Authors:  Justin Bailey; Shannon Waters
Journal:  J Am Board Fam Med       Date:  2008 May-Jun       Impact factor: 2.657

Review 5.  Bupropion sustained release: side effect profile.

Authors:  E C Settle
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

6.  Prevalence of psychosis, delusions, and hallucinations in clinical trials with bupropion.

Authors:  J A Johnston; C G Lineberry; C S Frieden
Journal:  Am J Psychiatry       Date:  1986-09       Impact factor: 18.112

7.  Diethylpropion, bupropion, and psychoses.

Authors:  R N Golden
Journal:  Br J Psychiatry       Date:  1988-08       Impact factor: 9.319

8.  Psychoses associated with bupropion treatment.

Authors:  R N Golden; S P James; M A Sherer; M V Rudorfer; D A Sack; W Z Potter
Journal:  Am J Psychiatry       Date:  1985-12       Impact factor: 18.112

9.  Organic mental disorders associated with bupropion in three patients.

Authors:  D Ames; W C Wirshing; M P Szuba
Journal:  J Clin Psychiatry       Date:  1992-02       Impact factor: 4.384

10.  Acute psychosis after administration of bupropion hydrochloride (Zyban).

Authors:  M Neumann; V Livak; H-W Paul; G Laux
Journal:  Pharmacopsychiatry       Date:  2002-11       Impact factor: 5.788

View more
  3 in total

1.  Agitated delirium associated with therapeutic doses of sustained-release bupropion.

Authors:  Diana R Mack; Liza Barbarello-Andrews; Mei T Liu
Journal:  Int J Clin Pharm       Date:  2011-11-23

2.  Unusual effects of nicotine as a psychostimulant on ambulatory activity in mice.

Authors:  Toyoshi Umezu
Journal:  ISRN Pharmacol       Date:  2012-03-20

3.  Brain regions and monoaminergic neurotransmitters that are involved in mouse ambulatory activity promoted by bupropion.

Authors:  Toyoshi Umezu; Yasuyuki Shibata
Journal:  Toxicol Rep       Date:  2016-06-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.